Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid TumorsThierry André, Susana Banerjee, Adriano Gravina et al.|JAMA Network Open|2023Cited by 120
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myelomaTorben Plesner, Paul G. Richardson, Peter Gimsing et al.|Blood|2016Cited by 110
Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple MyelomaTorben Plesner, Paul G. Richardson, Peter Gimsing et al.|Blood|2014Cited by 49
Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503)Torben Plesner, Paul G. Richardson, Tahamtan Ahmadi et al.|Blood|2015Cited by 40
Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma.Torben Plesner, Paul G. Richardson, Peter Gimsing et al.|Journal of Clinical Oncology|2014Cited by 36